ADXN

Addex Therapeutics Ltd Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website addextherapeutics.com
Employees(FY) 24
ISIN US00654J2069

Performance

-15.85%

-29.31%

-4.53%

-16.04%

+21.98%

YTD

+17.14%

Profile

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Advanced Technical Analysis

Technical Analysis of ADXN 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in momentum and trend direction. This combination suggests caution for potential investors, as all scores fall below the neutral threshold.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ADXN

Stock Rank

Recent News & Updates

2024-11-10 12:00
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024(Globenewswire)
2024-09-29 13:00
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update(Globenewswire)
2024-09-18 13:00
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit(Globenewswire)
2024-09-03 13:00
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-26 13:00
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration(Globenewswire)
2024-07-21 13:00
Addex's Partner Discontinues ADX71149 development in Epilepsy(Globenewswire)
2024-07-14 13:00
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)(Globenewswire)
2024-07-11 13:00
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)(Globenewswire)
2024-06-30 13:00
Addex Shareholders Approve All Resolutions at Annual General Meeting(Globenewswire)
2024-06-05 19:52
ADXN Stock Earnings: Addex Therapeutics Reported Results for Q1 2024(Investorplace)
2024-06-05 13:00
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-06-04 13:00
Addex Convenes Annual General Meeting 2024(Globenewswire)
2024-05-30 13:00
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024(Globenewswire)
2024-05-07 13:00
Addex to Present at Bio quity Europe 2024(Globenewswire)
2024-05-05 19:28
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-04-29 19:31
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-04-28 19:33
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-04-28 13:00
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study(Globenewswire)
2024-04-18 13:00
Addex to Present at the Swiss Biotech Day 2024(Globenewswire)
2024-04-17 18:52
ADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023(Investorplace)
2024-04-17 13:00
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-04-10 13:00
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024(Globenewswire)
2024-04-02 13:00
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders(Globenewswire)
2024-03-13 14:00
Addex to Present at the Bio-Europe Spring 2024 Conference(Yahoo Finance)
2024-01-30 12:00
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.(Yahoo Finance)
2024-01-08 12:00
Addex to Present at the Swiss Equities Baader Conference(Globenewswire)
2024-01-04 12:30
Addex to Present at Biotech Showcase 2024(Globenewswire)
2023-12-19 12:00
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting(Globenewswire)
2023-12-13 12:00
Addex Creates Treasury Shares(Globenewswire)
2023-11-28 12:21
Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts(Rttnews)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.